

Supplementary Table 1. Unadjusted and adjusted smoking frequencies in myositis phenotypes

	Unadjusted smoking frequency						Adjusted smoking frequency					
	Caucasians (n=330)		African-American (n=99)		Total Population (n=465)		Caucasians (n=330)		African-American (n=99)		Total Population (n=465)	
	N (+/total)	Freq (%)	N (+/total)	Freq (%)	N (+/total)	Freq (%)	N (+/total)	Freq (%)	N (+/total)	Freq (%)	N (+/total)	Freq (%)
Diagnosis												
Dermatomyositis	47/149	32%	5/28	18%	55/193	28%	51.9/149	35%	5.5/28	20%	49.7/193	26%
Polymyositis	92/176	52%	24/71	34%	124/267	46%	96.1/176	55%	26.1/71	37%	117.3/267	44%
ILD-negative	82/214	38%	15/51	29%	101/286	35%	90.7/214	42%	17.2/51	34%	95.5/286	33%
ILD-positive	54/103	52%	13/43	30%	74/161	46%	55.9/103	54%	13.9/41	32%	69.6/161	43%
MSA-negative	51/122	42%	9/28	32%	64/166	39%	55.4/122	45%	10.7/28	38%	62.6/166	38%
MSA-positive	60/144	42%	12/43	28%	76/195	39%	63.7/144	44%	14.2/43	33%	73.7/195	38%
ASA-negative	69/183	38%	14/45	31%	89/248	36%	72.5/183	40%	17.2/45	38%	85.6/248	35%
ASA-positive	42/83	51%	7/26	27%	51/113	45%	46.4/83	56%	7.7/26	30%	51.6/113	46%
Anti-Jo-1-negative	75/197	38%	15/54	28%	96/271	35%	79.2/197	40%	19.2/54	36%	93.7/271	35%
Anti-Jo-1-positive	35/68	51%	6/17	35%	43/89	48%	38.4/68	57%	5.6/17	33%	42.2/89	47%
Anti-PL-7-negative	105/255	41%	20/69	29%	133/348	38%	112.7/255	44%	23.5/69	34%	130.5/348	37%
Anti-PL-7-positive	3/6	50%	1/2	50%	4/8	50%	3.5/6	58%	1.2/2	62%	4.3/8	54%
Anti-PL-12-negative	106/259	41%	21/66	32%	135/349	39%	114.1/259	44%	23.8/66	36%	131.8/349	38%
Anti-PL-12-positive	2/2	100%	0/5	0%	2/7	29%	2/2	100%	0/5	0%	2.5/7	36%
Anti-OJ-negative	97/230	42%	19/66	29%	123/319	39%	103.7/230	45%	N/A	N/A	116.3/319	36%
Anti-OJ-positive	1/5	20%	No OJ+	N/A	1/5	20%	0.98/5	20%	N/A	N/A	0.7/5	15%
Anti-EJ-negative	97/233	42%	19/64	30%	123/320	38%	N/A	N/A	21.1/64	33%	117.0/320	37%
Anti-EJ-positive	No EJ+	N/A	0/2	0%	0/2	0%	N/A	N/A	0/2	0%	0/2	0%
Anti-KS-negative	96/233	41%	19/66	29%	122/322	38%	102.5/233	44%	N/A	N/A	116.3/322	36%
Anti-KS-positive	2/3	67%	No KS+	N/A	2/3	67%	2.3/3	78%	N/A	N/A	2.1/3	71%
Anti-Mi-2-negative	104/247	42%	20/67	30%	130/336	39%	114.4/247	46%	23.3/67	35%	129.3/336	38%
Anti-Mi-2-positive	4/14	29%	1/4	25%	7/20	35%	3.1/14	22%	1.3/4	33%	5.7/20	29%
Anti-MJ-negative	93/222	42%	19/65	29%	120/311	39%	98.4/222	44%	21.3/65	33%	115.4/311	37%
Anti-MJ-positive	5/15	33%	0/1	0%	5/16	31%	5.9/15	39%	0/1	0%	4.9/16	31%
Anti-SRP-negative	102/248	41%	17/61	28%	127/332	38%	110.6/248	45%	18.7/61	31%	123.9/332	37%
Anti-SRP-positive	6/13	46%	4/10	40%	10/24	42%	5.6/13	43%	5.3/10	53%	10.1/24	42%
Anti-p155/140-negative	90/206	44%	19/63	30%	115/290	40%	96.2/206	47%	20.9/63	33%	111.6/290	38%
Anti-p155/140-positive	7/29	24%	0/3	0%	9/35	26%	6.9/29	24%	0/3	0%	7.7/35	22%

MAA-negative	87/197	44%	16/40	40%	110/252	44%	92.3/197	47%	18.1/40	45%	106.3/252	42%
MAA-positive	22/65	34%	5/31	16%	28/105	27%	24.8/65	38%	6.5/31	21%	30.3/105	29%
Anti-PM/Scl-negative	105/248	42%	21/70	30%	134/341	39%	113.1/248	46%	24.5/70	35%	131.2/341	38%
Anti-PM/Scl-positive	3/13	23%	0/1	0%	3/15	20%	3.3/13	25%	0/1	0%	2.8/15	18%
Anti-KU-negative	98/235	42%	19/65	29%	124/322	39%	104.4/235	44%	21.3/65	33%	117.9/322	37%
Anti-KU-positive	0/1	0%	0/1	0%	0/3	0%	0/1	0%	0/1	0%	0/3	0%
Anti-U1RNP-negative	102/242	42%	20/59	34%	130/324	40%	109.0/242	45%	23.1/59	39%	125.9/324	39%
Anti-U1RNP-positive	7/20	35%	1/12	8%	8/33	24%	8.4/20	42%	1.3/12	11%	9.0/33	27%
Anti-U2RNP-negative	83/201	41%	14/56	25%	102/274	37%	88.7/201	44%	N/A	N/A	90.9/274	33%
Anti-U2RNP-positive	1/4	25%	No U2+	N/A	1/4	25%	1.1/4	29%	N/A	N/A	0.8/4	20%
Anti-SSA/Ro-negative	96/232	41%	18/49	37%	121/299	40%	101.0/232	44%	21.1/49	43%	117.9/299	39%
Anti-SSA/Ro-positive	13/30	43%	3/22	14%	17/58	29%	10.3/30	34%	3.8/22	17%	18.7/58	32%
Anti-SSB/La-negative	71/161	44%	17/49	35%	94/228	41%	76.6/161	48%	20.6/49	42%	91.0/228	40%
Anti-SSB/La-positive	4/8	50%	0/4	0%	4/13	31%	4.2/8	52%	0/4	0%	3.7/13	29%
Anti-Smith-negative	107/257	42%	18/65	28%	133/346	38%	114.6/257	45%	21.4/65	33%	128.8/346	37%
Anti-Smith-positive	1/4	25%	1/3	33%	2/7	29%	1.4/4	34%	1.5/3	50%	2.6/7	37%

Smoking frequency is adjusted by age at the time of evaluation, gender and race when appropriate. Each color pairing represents the two columns of a single 2x2 contingency table and percentage presents frequency of ever-smokers in each group. ILD= interstitial lung disease; MSA= myositis-specific autoantibodies; ASA= anti-synthetase autoantibodies; N/A= not applicable.